Suvizumab

Suvizumab (KD-247), a neutralizing antibody against HIV-1, effectively neutralizes strains HIV-1 MN, HIV-1 SF2, and HIV-1 89.6, exhibiting IC50 values of 0.1 µg/mL, 1.0 µg/mL, and 0.2 µg/mL, respectively. It demonstrates a significant reduction in viral load, indicating its efficacy in preventing HIV infection. Suvizumab is also well-tolerated, further supporting its potential as a preventative treatment for HIV [1] [2].